

FIG.1

Malignant Breast
96102003G H9C65



FIG.2A

Malignant Breast
9609C033R H9C65




FIG.2B

Normal Breast.
9712C030G H9C65



FIG.2C

MB8 Cell Line
H9C65




FIG.2D

Malignant Breast
96102003G H95C30




FIG.3A

Malignant Breast
9609C033R H95C30




FIG.3B

Normal Breast
9712C030G H95C30



FIG.3C

MB8 Cell Line
H95C30




FIG.3D





FIG.4A



anti-BU101 PAb 10923
FIG.4B

1 2 3 4 3



anti-Mam PAb 10931

FIG.4C



anti-myc MAb

FIG.5A




FIG.5B




FIG.6A






FIG.6B



10918 10923 11543 10931
 Polyclonal Antisera, 1:5000

FIG.6C



H85 H68 H111 myc
 Monoclonal Antibodies 1:50

FIG.6D

1 2



FIG. 7




FIG. 8A




FIG. 8B




FIG.9




FIG.10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15





FIG.11A

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15




FIG.11B



anti-BU101.3, 10923, 1:5000
sample reduced and boiled


FIG.12A



anti-MAM.1, 10931, 1:5000
sample reduced and boiled


FIG.12B

Reduced								Not Reduced							
42	43	44	45	46	47	48	42	43	44	45	46	47	48		




Polyclonal Antibody 10923
anti-BU101.3

FIG.13A




Polyclonal Antibody 10931
anti-MAM.1

FIG.13B




anti-BU101 polyclonal 10923

FIG.14A



anti-Mam polyclonal

FIG.14B



anti-myc, 1:5000

FIG.15

Met	Lys	Leu	Ser	Val	Cys	Leu	Leu	Leu	Val	Thr	Leu	Ala	Leu	Cys	Cys
1				5					10					15	
Tyr	Gln	Ala	Asn	Ala	Glu	Phe	Cys	Pro	Ala	Leu	Val	Ser	Glu	Leu	Leu
			20					25					30		
Asp	Phe	Phe	Phe	Ile	Ser	Glu	Pro	Leu	Phe	Lys	Leu	Ser	Leu	Ala	Lys
		35					40					45			
Phe	Asp	Ala	Pro	Pro	Glu	Ala	Val	Ala	Ala	Lys	Leu	Gly	Val	Lys	Arg
	50					55					60				
Cys	Thr	Asp	Gln	Met	Ser	Leu	Gln	Lys	Arg	Ser	Leu	Ile	Ala	Glu	Val
65					70					75				80	
Leu	Val	Lys	Ile	Leu	Lys	Lys	Cys	Ser	Val						
				85					90						

FIG.16

ASSEMBLY OF BS106 FROM INDIVIDUAL EXPRESSED TAGS




FIG.17

>BS106 CONSENSUS




CGGCTCGAGCTCTTAGGCTTTGAAGCATTTTTGTCTGTGCTCCCT
GATCTTCAGGTCACCACCATGAAGTTCTTAGCAGTCCTGGTACTC
TTGGGAGTTTCCATCTTTCTGGTCTCTGCCAGAATCCGACAACA
GCTGCTCCAGCTGACACGTATCCAGCTACTGGTCCTGCTGATGAT
GAAGCCCCTGATGCTGAAACCACTGCTGCTGCAACCACTGCGACC
ACTGCTGCTCCTACCACTGCAACCACCGCTGCTTCTACCACTGCT
CGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTTCCG
AATGGTAGAGTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTG
CAATTGGTCACAACTATTATGCTTCCTGTGATTTTCATCCAATA
CTTACCTTGCCTACGATATCCCCCTTATCTCTAATCAGTTTATTT
TCTTTCAAATAAAAAATAACTATGAGCAACATAAAAAAAAAAAAAA


FIG.18A

>BS106 TRANSLATION

MKFLAVLVLLGVSI FLVSAQNPTTAAPADTYPATGPADDEAPDAE
TTAAATTATTAAPT TATTAASTTARKDIPVLPKWVGDLPNGRVCP


FIG.18B






Anti-BU101.3 Polyclonal

FIG.20A




Anti-Mam.1 Polyclonal

FIG.20B



Anti-BU101.3 Polyclonal

FIG.20C



Anti-Mam.1 Polyclonal


FIG.20D

Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mamaglobin	CK19	
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)	N=95
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)	N=90
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)	N=85
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)	N=85
ER	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)	N=99
PR	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)	N=99
HER2	-0.12 (NS)	0.36 (p=0.003)	0.11 (NS)	0.02 (NS)	N=67
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)	N=77
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS)	N=101
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)	N=101
Mamm	0.37 (p=0.0001)	0.004 (NS)	-----	0.07 (NS)	N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. **NS=not significant**

FIG.21



09975502 .030702

PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants: J. Henslee, *et al.*

Serial No.: 09/975,502

Filed: October 11, 2001

For: REAGENTS AND METHODS USEFUL
FOR DETECTING DISEASES OF THE
BREAST

Case No.: 5972.US.P7

Group Art No.: 1645

Examiner: (not yet assigned)

Certificate of Mailing Under 37 C.F.R. §1.10(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231, on:

Date of Deposit:

Kimberly A. Iorio 2/28/02
Kimberly A. Iorio Date

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Assistant Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231

Dear Sir:

In response to the Notice to File Missing Parts of Application dated November 11, 2001 in the patent application identified above, applicants submit herewith the following: 1) an executed Declaration and Power of Attorney; 2) substitute Drawings in compliance with 37 CFR §1.84; 3) paper copy of the Sequence Listing; 4) computer readable form copy of Sequence Listing; and 5) Statement to Support Filings and Submissions in accordance with 35 CFR §§1.821-1.825.

The Commissioner is hereby authorized to charge the required surcharge of \$130.00 to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.



23492

ABBOTT LABORATORIES
Telephone: (847) 935-1729
Facsimile: (847) 938-2623

Respectfully submitted,
J. Henslee, *et al.*

Cheryl L. Becker
Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants